Publications

Manuscripts in refereed journals: 

  1. Marchetti, D., Blaustein, D.L., and Giacomoni, D. Liposome-mediated insertion of intact DNA into isolated nuclei-potential for a new in vitro transcription system. Exp. Cell. Res., 149: 177-187, 1983.
  2. Thorpe, L. W., Stach, R.W., Hashim, G.A., Marchetti, D., and Perez-Polo, J.R. Receptors for nerve growth factor on rat spleen mononuclear cells. Journ. Neurosci. Res., 17: 128-134, 1987.
  3. Marchetti, D., and Perez-Polo, J.R. Nerve growth factor receptors in human neuroblastoma cells.  Journ. Neurochem., 49: 475-486, 1987.
  4. Marchetti, D., Stach, R.W., Saneto, R.P., deVellis, J., and Perez-Polo, J.R. Binding constants of soluble nerve growth factor receptors in rat oligodendrocytes and astrocytes in culture. Biochem. Biophys. Res. Comm., 147: 422-427, 1987.
  5. Wright, L.L., Marchetti, D., and Perez-Polo, J.R. Effects on gonadal steroids on nerve growth factor receptors in sympathetic and sensory ganglia of neonatal rats. Int. Journ. Dev. Neurosci., 6: 217-222, 1988.
  6. Linthicum, D.S., Bolger, M.B., Kussie, P.H., Albright, A., Linton, A., Combs, S., and Marchetti, D. Analysis of idiotypic and anti-idiotypic antibodies as models of receptor and ligand.  Clin. Chem., 33: 1676-1680, 1988.
  7. Marchetti, D., Van, N.T., Gametchu, B., Thompson, E.B., Kobayashi, Y., Watanabe, F., and Barlogie, B. Flow cytometric analysis of glucocorticoid receptor using monoclonal antibody and fluoresceinated ligand probe. Cancer Research, 49: 863-969, 1989.
  8. Morgan, G., Thorpe, L.W., Marchetti, D., and Perez-Polo, J.R. Expression of nerve growth factor receptors by human peripheral blood mononuclear cells. Journ. Neurosci. Res., 23: 41-45, 1989.
  9. Kussie, P.H., Marchetti, D., Sherman, M., and Linthicum, D.S. Molecular analysis of monoclonal idiotypes and anti-idiotypes. Methods Enzymology, 178: 91-107, 1989.
  10. McManaman, J.L., Oppenheim, R.W., Prevette, D., and Marchetti, D. Rescue of motoneurons from naturally occurring cell death by a purified skeletal muscle polypeptide: In vivo and in vitro effects of the choline acetyltransferase development factor (CDF). Neuron, 4: 891-898, 1990.
  11. Marchetti, D., and McManaman, J.L. Characterization of nerve growth factor binding to embryonic rat spinal cord neurons. Journ. Neurosci. Res., 27: 211-218, 1990.
  12. Perez-Polo, J.R., Werrbach-Perez, K., Marchetti, D., Morgan, B., Tagliatatela, G., Ramacci, M. T., and Angelucci, L. Nerve growth factor activity and aging in the central nervous system. Int. Journ. Clin. Pharm. Res., 10: 15-26, 1990.
  13. Werrbach-Perez, K., Jackson, G., Marchetti, D., Morgan, B., Thorpe L., and Perez- Polo, J. R. Growth factor-mediated protection in the aging central nervous system. Prog. Brain Res., 86: 183-194, 1990.
  14. Marchetti, D., Haverkamp, L.J., Clark, R.C., and McManaman, J.L. Ontogeny of high- and low-affinity nerve growth factor receptors in the lumbar spinal cord of the developing chick embryo.  Developmental Biology, 148: 306-313, 1991.
  15. Marchetti, D., Menter, D.G., Jin, L., Nakajima, M., and Nicolson, G.L. Nerve growth factor effects on human melanoma cell invasion. Int. Journ. Cancer, 55: 692-699, 1993.
  16. Herrmann, J.L., Menter, D.G., Marchetti, D., Hamada, J.-I., Nakajima M., and Nicolson, G. L. Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol. Biol. Cell, 4(11): 1205-1216, 1993.
  17. Nicolson, G.L., Nakajima, M., Herrmann, J.H., Menter, D.G., Cavanaugh, P.G., Sik Park, J., and Marchetti, D. Malignant melanoma metastasis to brain: role of degradative enzymes and responses to paracrine growth factors. Journ. Neuro-Oncology, 18: 139-149, 1994.
  18. Cohen, I.R., Murdoch, A.D., Naso, M.F., Marchetti D., Bernd, D., and Iozzo, R. Abnormal expression of perlecan proteoglycan in metastatic melanoma. Cancer Research, 54: 5771-5774, 1994.
  19. Marchetti, D., McCutcheon, I., Ross, M.I., and Nicolson, G.L. Inverse expression of neurotrophin receptors and neurotrophins at the invasion front of brain-metastatic human melanoma tissues. Int. Journ. Oncology, 7: 87-94, 1995.
  20. Menter, D.G., Herrmann, J.L., Marchetti, D., and Nicolson, G.L. Involvement of neurotrophins and growth factors in brain metastasis formation.  Invasion and Metastasis 14: 372-394, 1995.
  21. Marchetti,  D.,  McQuillan,  D.,  Spohn  W.C.,  Carson,  D.D.,  and  Nicolson,  G.L. Neurotrophin stimulation of human melanoma cell invasion: selected NT enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations. Cancer Research, 56(2): 2856-2863, 1996.
  22. Marchetti, D., Shouchun, L., Spohn, W.C., and Carson, D.D. Inhibition of heparanase activity by heparan sulfate interacting peptide (HIP) and reciprocal HIP binding blocking to cell-surface heparan sulfate subpopulations due to heparanase action. The Journ. of Biol. Chemistry, 272(25): 15891-15897, 1997.
  23. Marchetti, D., and Nicolson, G.L. Heparanase in tumor metastasis: degradation of specific heparan sulfate subpopulations due to heparanase action. Adv. Enzyme Reg., 37: 111-134, 1997.    
  24. Marchetti, D. Specific degradation of subendothelial matrix  proteoglycans  by human brain-metastatic melanoma/brain endothelial cell heparanases. Journ. Cell. Physiology, 173 (3): 334-342, 1997.
  25. Marchetti, D., and Nicolson, G.L. Heparanase and heparan sulfate proteoglycans processing in tumor metastasis.  Journ. Inv. Dermatology, 2: 99-105, 1997.
  26. Marchetti, D., Parikh, N., Sudol, M., and Gallick, G.E. Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells.  Oncogene, 16 (25): 3253-3260, 1998.
  27. Walch, E.T., Albino, A.P., and Marchetti, D. Over-expression of the low-affinity p75 neurotrophin receptor correlates with augmented invasion and heparanase production in human malignant melanoma cells.  Int. Journ. Cancer, 82: 112-120, 1999.
  28. Walch, E.T., and Marchetti, D.  Role of neurotrophins and neurotrophin receptors in the in vitro invasion and heparanase production of human prostatic cancer cells. Clin. & Exp. Metastasis, 17(4): 307-314, 1999.
  29. Marchetti, D., Li, J., and Shen, R-J. Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Research, 60: 4767-4770, 2000.
  30. Marchetti, D., and Nicolson, G.L. Human heparanase: a molecular determinant of brain metastasis. Adv. Enzyme Reg., 41: 343-360, 2001.
  31. Marchetti, D., Reiland, J., Erwin, B., and Roy, M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int. Journ. Cancer, 104(2): 167-174, 2003.
  32. Marchetti, D., Murry, B., Galjour, J., and Greiter-Wilke, A. Human melanoma TrkC: its association via a purine-analog-sensitive-kinase activity. Journ. Cell. Biochemistry, 88(5): 865-872, 2003.
  33. Marchetti, D., Aucoin, R., Blust, J., Murry, B., and Greiter-Wilke, A. The p75 neurotrophin receptor acts as a survival receptor in brain-metastatic melanoma. Journ. Cell.  Biochemistry, 91(1): 206-215, 2004.
  34. Reiland, J., Sanderson, R.D., Waguespack, M., Barker, S., Long, R., Carson, D.D., and Marchetti, D. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. Journ. of Biol. Chemistry, 279(9): 8047- 8055, 2004.
  35. Aucoin, R., Reiland, J., Roy, M., and Marchetti, D.  Dominant-negative CREB Inhibits heparanase functionality and melanoma cell invasion.  Journ. Cell. Biochem., 93(2): 215-223, 2004.
  36. Roy, M., Reiland, J., Chouljenko, V., Kousoulas, K.G., and Marchetti, D.  Antisense mediated suppression of heparanase gene inhibits melanoma cell invasion. Neoplasia, 7(3): 253-262, 2005.
  37. Murry, B.P., Greiter-Wilke, A., Paulsen, D.B., Hiatt, K.M., Beltrami, C.A., and Marchetti, D.         Selective heparanase localization in malignant melanoma cancers. Int. Journ. Oncology, 26: 345-352, 2005.
  38. Denkins, Y., Kempf, D., Ferniz, M., Nileshwar, S., and Marchetti, D. Role of omega-3 polyunsaturated fatty acids on COX-2 metabolism in brain-metastatic melanoma. Journ. Lipid   Res., 46: 1278-1284, 2005.
  39. Sinnappah-Kang, N.D., Kaiser, A.J., Blust, B., and Marchetti, D. Heparanase, TrkC, and p75NTR: their functional involvement in human medulloblastoma cell invasion. Int. Journ. Oncology,  27: 617-626, 2005.
  40. Murry, B.P., Blust, B., Singh, A., Foster, T., and Marchetti, D. Heparanase mechanisms of melanoma metastasis to the brain: development and use of a brain slice model.  Journ. Cell.  Biochem., 97(2): 217-225, 2006.
  41. Moretti, M.*, Sinnappah-Kang, N.*, Toller, M., Curcio, F., and Marchetti, D. HPSE-1 expression and functionality in differentiating neural cells. Journ. Neurosci. Res., 83: 694- 701, 2006.   *Equal contribution.
  42. El-Sayed, K., Youssef, D.T.A., Marchetti, D., and Shaala, L.A.  Bioactive natural and semisynthetic latrunculins. The Journ. of Nat. Products, 69(2): 219-223, 2006.
  43. Swapnali, S.S., Youssef, D.T.A., Reiland, J., Ferniz, M., Marchetti, D., and El- Sayed, K.A.   Biocatalytic and antimetastatic studies of the marine cembranoids sarcophine and 2-epi-16-deoxysarcophine. The Journ. of Nat. Products, 69(7): 1010-1013, 2006.
  44. Reiland, J., Kempf, D., Roy, M., Denkins, Y., and Marchetti, D. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia, 8(7): 596-606, 2006.
  45. Sinnappah-Kang, N., Mrak, R.E., Paulsen, D.D., and Marchetti, D. Prognostic implications of heparanase and TrkC/p75NTR expression in human medulloblastoma.  Clin.&  Exp. Metastasis, 23: 55-63, 2006.
  46. Brown, A.J., Alicknavitch, M., D’Souza, S. S., Daikoku, T., Kirn-Safran, C., Marchetti, D., Carson, D.D., and Farach-Carson, M.C. Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone, 43(4): 689-699, 2008.
  47. S’Souza D., Yang W., Marchetti, D., Muir C., Julian J., Farach-Carson M., and Carson D.D.  HIP/RLP29 antagonizes VEGF and FGF2 responses.  Journ. Cell. Biochem., 105(5): 1183-1193, 2008.
  48. Roy M. and Marchetti, D. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. Journ. Cell. Biochem., 106(2): 200- 209, 2009.
  49. Zhang L., Sullivan P. S., Suyama , J., and Marchetti, D.  EGF - induced heparanase nucleolar localization augments DNA Topoisomerase I activity in brain-metastatic breast cancer. Mol. Cancer Res., 8(2): 278-290, 2010.
  50. Ridgway L. D., Wetzel M., and Marchetti, D.  Modulation of GEF-H1 induced signaling by heparanase in brain-metastatic melanoma cells. Journ. Cell. Biochemistry, 111(5):1299-1309, 2010 (selected as feature article).
  51. Ridgway L. D., Wetzel M., and Marchetti, D. Heparanase modulates Hh and Wnt3a signaling in human medulloblastoma cells.  Exp. & Ther. Medicine, 2: 229-237, 2011.
  52. Zhang L., Sullivan P.S., Gunaratne P., Goodman J.C., and Marchetti, D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Research – Priority Report, 71(3): 645-654, 2011 - selected as one of six Breaking Advances - Highlights from recent cancer literature.  Cancer Research, 71 (6): 2025, 2011.
  53. Guo L., Fan D., Zhang F., Lee J.-S., Price, J., Fidler I., Marchetti, D., and Langley R. Selection of brain metastasis - initiating breast cancer cells according to growth on hard agar. Am. Journ.  Pathology, 178 (5): 2357-2366, 2011.
  54. Ridgway L. D., Wetzel M., Epstein A., and Marchetti, D.  Heparanase - induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells.  Molecular Cancer Research, 10 (6):  689-702, 2012.
  55. Zhang L, Ridgway L, Wetzel M., Ngo J., Yin W., Kumar D., Goodman J.C., Groves M., and Marchetti, D. The identification and characterization of breast cancer CTCs with brain metastatic competence. Science Translational Medicine, 5 (180): 84-93, 2013. Commentary by Michael Clarke. Nature Biotech., 31(6): 504-5, 2013.
  56. Camacho L, Guerrero P., and Marchetti, D.  MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. PLoS One, 16; 8(9): e73790, 2013.
  57. Guerrero P., Yin W, Camacho L, and Marchetti, D. Oncogenic role of Merlin/NF2 in glioblastoma. Oncogene, 2014 Jul 21. doi: 10.1038/onc.2014.185, 2014.
  58. Capuana S., Hoyos V., Chakraborty R., Savoldo B., Marchetti D., and Dotti G.P. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes, Nature Medicine, in revision, 2014.
  59. Zhang L., Ngo J., Wetzel MA, and  Marchetti, D.  Heparanase mediates a novel mechanism in  lapatinib-resistant brain metastatic breast cancer.  Neoplasia, In Press, 2015.

Reviews in refereed journals, book chapters, and invited expert commentary:

  1. Marchetti, D. The molecular components of cells. In: Biology I. (De Re P., Ed), vol. 1, pp. 19-32, Bulgarini, Florence, Italy, 1984.
  2. Marchetti, D. Catabolism and the generation of phosphate-bond  energy.  In: Biology I (De Re, P. Ed.), vol. 1, pp. 45-51, Bulgarini, Florence, Italy, 1984.
  3. Marchetti, D. Replication, transcription and translation of genetic information. In: Biology II.  (De Re, P., Ed.) vol. 2, pp. 43-66, Bulgarini, Florence, Italy, 1984.
  4. Perez-Polo, J. R., Beck, C., Marchetti, D., Morgan, B., Thorpe, L. W., and Werrbach-Perez, K. Role of nerve growth factor receptors in intercellular communication. In: Advances in Myochemistry, (Benzi G., Ed.), pp. 135-144, John Libbey Eurotext Ltd., 1987.
  5. Perez-Polo, J. R., Werrbach-Perez, K., Jackson, G., Beck, C., Marchetti, D., Morgan, B., Taglialatela, G., Ramacci, M. T., and Angelucci, L. Neurotrophic factors in aged rodent central nervous system. In: Aging and Dementia: New Trends in Diagnosis and Therapy, pp. 297-318, Alan R. Liss, 1990.
  6. Nicolson, G.L., Menter, D., Herrmann, J., Cavanaugh, P., Jia, L., Hamada, J., Yun Z., and Marchetti, D. Tumor metastasis to brain: role of endothelial cells, neurotrophins and paracrine growth factors.  Critical Reviews in Oncogenesis, 5(5): 451-471, 1994.
  7. Nicolson, G.L., Menter, D.G., Herrmann, J.L., Yun, Z., Cavanaugh, P., and Marchetti, D.  Brain metastasis: role of trophic, autocrine and paracrine factors in tumor invasion  and  colonization  of  the  central  nervous  system.   In:  Attempts  to  understand metastasis formation II (Gunthert U. and Birchmeier W. Eds.), pp. 90-115, 1996.
  8. Marchetti, D.  Human heparanase: a mediator of tumor metastasis and angioge- nesis. Cancer Research Alert, 2(7): 73-76, 2000.
  9. Marchetti, D. Brain-metastasis associated genes. In: Cancer metastasis-related genes (D. Welch Ed.), Cancer Metastasis: Biology and Treatment series (Albin, R.J., Jiang W.G. Eds.), Kluwer Acad. Publ., pp. 89-108, 2002.
  10. Marchetti, D. “Heparanase: a target for brain tumor therapy?” Expert Review Neurotherapeutics, 2(4): 89-93, 2002.
  11. Marchetti, D., Denkins, Y., Reiland, J., Greiter-Wilke, A., Galjour, J., Murry, B., Blust, J., and Roy, M. Brain-metastatic melanoma: a neurotrophic perspective. Pathol. Oncol. Res., 9(3): 147-158, 2003.
  12. Denkins, Y., Reiland, J., Greiter-Wilke, A., Galjour, J., Murry, B., Blust, J., Roy, M., and Marchetti, D. Brain-metastatic melanoma: roles of neurotrophins. Neuro-Oncology, 6(2): 154-165, 2004.
  13. Marchetti, D., Kaiser, A.J., Blust, B.E., Mrak, M.E., and Sinnappah-Kang, N.D. Neurotrophin receptors and heparanase in brain tumors invasion. In:      “Trends in Brain Cancer Research” (AV Yang Ed.), Nova Publishers Inc., pp. 253-280, 2006.
  14. Marchetti, D., Mrak, R.E., Paulsen, D.D., and Sinnappah-Kang, N.D.  Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion.  Journ. of Exp. Clin. Cancer Res., 26: 5-23, 2007.
  15. Marchetti, D. Senior Editor, special book issue: “Brain Metastasis” by invitation International Journal of Molecular Sciences (IJMS), MDPI  AG, Basel, Switzerland, 2013.
  16. Marchetti, D.  Guest Editor, special issue: “Brain Metastasis 2014” International Journal of Molecular Sciences (IJMS), MDPI  AG, Basel, Switzerland, 2014.
  17. Marchetti, D. Expert commentary:  “Unraveling Metastasis with Circulating Tumor Cells”, College of American Pathologists - CAP Today, May 2014.
  18. Marchetti, D. Expert commentary:  “Advances in Capturing Elusive Circulating Tumor Cells”  BioScience Technology, July 2014.
  19. Marchetti, D. Expert commentary:  “Beyond Counting:  New Way to Use Circulating Tumor Cells”    The Journ. Natl. Cancer Institute, Vol.10: 10, 4-9, 2014.
  20. Marchetti, D. Guest Editor, special issue: “Circulating Tumor Cells” Journal of Circulating Biomarkers, 2014.

Abstracts of presentations at scientific meetings:

  1. Werrbach-Perez, K., Young, S., Marchetti, D., and Perez-Polo, J. R. Restorative effects of nerve growth factor on injured neurons in vitro. Fifth International Meeting of the International Society for Developmental Neuroscience, Chieti, Italy, 1984.
  2. Marchetti, D., and Perez-Polo, J. R. Isolation of nerve growth factor receptor molecular species. Tenth International Meeting of the International Society for Neurochemistry, Riva del Garda, Italy, 1985.
  3. Marchetti, D., Stach, R. W., Thorpe, L. W., and Perez-Polo, J. R. Nerve growth factor receptors on rat lymphocytes. Satellite meeting, Tenth International Meeting of the International Society of Neurochemistry, Iraklion, Crete, Greece, 1985.
  4. Marchetti, D., Van, N. T., Thompson, E. B., and Barlogie, B. Flow cytometric analysis of glucocorticoid receptor (GR) by means of a monoclonal antibody to GR and fluoresceinated cortisol probe. American Association of Cancer Research (A.A.C.R.) Meeting, Atlanta, GA, 1987.
  5. Beck, C., Morgan, B., Stach, R. W., Marchetti, D., Thorpe, L. W., and Perez-Polo, J.R. Structural features of nerve growth factor receptors found on neuronal versus immunologic cell types. Seventeenth Annual Meeting of the Society for Neuroscience, New Orleans, LA, 1987.
  6. Goldman-Leikin, R. E., Salwen, H. R., Herst, C. V., Marchetti, D., Selvanayagan, P., LeBeau, M. M., Weitzman, S. A., and Rosen, S. T. Molecular characterization of MM.1, a new Epstein-Barr virus negative human melanoma cell line. American Association of Cancer Research (A.A.C.R.) Meeting, New Orleans, LA, 1988.
  7. Marchetti, D., Kussie, P. H., Linthicum, D. S., and Glasel, J. A. Mimicry of morphine receptor by monoclonal antibodies to morphine. Twelfth International Meeting for the International Society for Neurochemistry, Algarve, Portugal, 1989.
  8. Shan, D. E., Beck, C., Marchetti, D., and Perez-Polo, J. R. Characterization of nerve growth factor receptor on PC12 cells using receptor binding assay and high- performance liquid chromatography. Twelfth International Meeting for the International Society for Neurochemistry, Algarve, Portugal, 1989.
  9. Marchetti, D., and McManaman, J. L. Presence and cellular distribution of high- affinity NGF receptors in embryonic rat spinal cords. Twenty-first Meeting of the American Society for Neurochemistry, Phoenix, AZ, 1990.
  10. Marchetti, D., Haverkamp, L. J., Clark, R. C., and McManaman, J. L. Nerve growth factor receptor expression in the developing chick embryo. Twentieth Meeting of the American Society for Neuroscience, St. Louis, MO, 1990.
  11. Herrmann, J., Nakajima, M., Menter, D., Hamada, J.-I., Marchetti, D., Grossfield, J., and Nicolson, G. L. A novel 120 kDa fibronectinase secreted by metastatic melanoma cells: potential role for NGF regulation. Advances in the Biology and Clinical Management of Melanoma, Houston, TX, 1991.
  12. Marchetti, D., Hamada, J., Herrmann, J. H., Menter, D. G., and Nicolson, G. L. Nerve growth factor effects on human melanoma cell invasion. Fourth International Congress, Metastasis Research Society, Paris, France, 1992.
  13. Marchetti, D., Kapoor, R., Nakajima, M., and Nicolson, G. L.  Nerve growth factor induces specific degradation of heparan sulfate proteoglycan in human melanoma cells. Eighty-Fourth American Association of Cancer Research (A.A.C.R.) Meeting, Orlando, FL, 1993.
  14. Menter, D. G., Herrmann, J. L., Marchetti, D., Hamada, J.-I., Kerbel, R. S., Nakajima, M., and Nicolson, G. L. A functional role for the low-affinity p75 nerve growth factor receptor in human melanoma progression to the invasive phenotype.  Eighty-Fourth A.A.C.R. Meeting, Orlando, FL, 1993.
  15. Kapoor, R., Marchetti, D., Nakajima, M., and Nicolson, G. L. Enhanced brain melanoma  cell  metastasis  results  from  degradation  of  heparan  sulfate  proteoglycan   induced by nerve growth factor, Becton-Dickinson Symposium on Extracellular Matrix, Boston, MA, 1993.
  16. Marchetti, D., Herrmann, J. H., Menter, D. G., and Nicolson, G. L. Neurotrophin-3 effects on human melanoma cell invasion. American Society of Cell Biology (A.S.B.C.) Meeting, New Orleans, LA, 1993.
  17. Kapoor, R., Marchetti, D., Nakajima, M., and Nicolson G. L. Enhanced brain melanoma cell metastasis results from degradation of heparan sulfate proteoglycan induced by nerve growth factor. A.S.C.B.  Meeting, New Orleans, LA, 1993.
  18. Herrmann, J. L., Menter, D. G., Marchetti, D., Hamada, J-I., and Nicolson G. L. Nerve growth factor mediated matrix invasion by human melanoma cells expressing p145 TrkC and overexpressing low-affinity p75 NGFR receptors. Forty-sixth Ann. Meeting Fund. Cancer Research, Houston, TX, 1993.
  19. Marchetti, D., Menter, D. G., Kapoor, R., Pencil, S., Herrmann, J. L., Nakajima, M., and Nicolson, G. L. Neurotrophins effects on human melanoma cell invasion. Forty-sixth Ann. Meeting of Fundamental Cancer Research, Houston, TX, 1993.
  20. Herrmann, J. L., Menter, D. G., Marchetti, D., and Nicolson, G. L. Nerve growth factor mediates matrix invasion by human melanoma cells expressing p145 TrkC and overexpressing low-affinity p75 NGFR receptors. Third University of Texas System Triangle Meeting, Dallas TX, 1994.
  21. Marchetti, D., Cohen, I., Nakajima, M., Iozzo, R., and Nicolson, G. L.  Specific degradation  of  perlecan  and  its expression  regulation  by  the  neurotrophins  in  human malignant melanoma. Clinical & Exp. Metastasis Meeting, Washington, D.C., 1994.
  22. Marchetti, D., Ross, M. I., McCutcheon, I., and Nicolson, G. L. Inverse expression of neurotrophin receptor and nerve growth factor at the invasion front of brain-metastatic human melanoma tissues. Eighty-fifth A.A.C.R. Meeting, San Francisco, CA, 1994.
  23. Marchetti, D., Cohen, I., Nakajima, M., Iozzo, R., and Nicolson, G. L. Specific degradation of perlecan and its expression regulation by the neurotrophins in human malignant melanoma. Thirty-eighth Annual International Conference on Malignant Melanoma, Houston, TX, 1995.
  24. Marchetti, D., McCutcheon, I., Ross, M., and Nicolson, G. L. Increased neurotrophins and heparanase levels at the invasion front of brain-metastatic human melanoma tissues: a comparative study. Thirty-eighth Annual International Conference on Malignant Melanoma, Houston, TX, 1995.
  25. Marchetti, D., Ross, M. I., McCutcheon, I., and Nicolson, G. L. Inverse expression of neurotrophin receptor and nerve growth factor at the invasion front of brain-metastatic human melanoma tissues. Thirty-eighth Annual International Conference on Malignant Melanoma, Houston, TX, 1995.
  26. Nicolson, G. L., Herrmann, J. L., Menter, D. G., and Marchetti, D. Neurotrophin- stimulated human malignant melanoma cell extracellular matrix invasion and survival mediated by the low-affinity neurotrophin receptor p75NTR: melanoma p75NTR functions independent of TrkA and requires a purine analogue-sensitive kinase for signalling. Thirty- eighth Annual International Conference Malignant Melanoma, Houston, TX, 1995.
  27. Marchetti,  D.,  McCutcheon,  I.,  Ross,  M.,  and  Nicolson,  G.  L. Increased neurotrophins and heparanase levels at the invasion front of brain-metastatic human melanoma tissues: a comparative study.  Eighty-sixth  A.A.C.R. Meeting, Toronto, Canada, 1995.
  28. Marchetti, D., McQuillan, D., Carson, D., and Nicolson, G. L. Selected NT enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations. Eighty-seventh A.A.C.R. Meeting, Washington, D.C., 1996.
  29. Marchetti, D., and Nicolson, G. L. Selected neurotrophin regulation of heparanase activity and degradation of specific heparan sulfate subpopulations due to heparanase action. Adv. in Enzyme Reg. Meeting, Indiana University Conference Center, Indianapolis, IN, 1996.
  30. Marchetti, D. Selected neurotrophin enhancement of heparanase activity and degradation of specific heparan sulfate subpopulations due to heparanase action in human malignant melanoma. Sixth International Congress of the Metastasis Research Society, Gent, Belgium, 1996.
  31. Marchetti, D. Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma/brain-endothelial cell heparanases. Sixth International Congress of the Metastasis Research Society, Gent, Belgium, 1996.
  32. Marchetti, D. Enzymatic degradation of subendothelial matrix proteoglycans. Eighty-eighth  A.A.C.R. Meeting, San Diego, CA, 1997.
  33. Marchetti, D. Tumor and endothelial cell heparanases. Cancer and the Central Nervous System: The Fortieth Annual Clinical Conference, Houston, TX, 1997.
  34. Marchetti, D. Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain-endothelial cell heparanases. Cancer and the Central Nervous System: The Fortieth Annual Clinical Conference, Houston, TX, 1997.
  35. Marchetti, D., Parikh, N., Sudol, M., and Gallick, G.E. Enhancement of protein tyrosine kinase c-Yes, but not c-Src, by select neurotrophins in human brain-metastatic melanoma cells.  Fiftieth Annual Symposium on Fundamental Cancer Research, Houston, TX, 1997.
  36. Marchetti, D., Shouchun, L., Spohn, W. C., and Carson, D. D. Heparanase and a synthetic peptide of HS-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate. Fiftieth Annual Symposium on Fundamental Cancer Research, Houston, TX 1997.     
  37. Marchetti, D. Specific degradation of subendothelial matrix proteoglycans by human brain-metastatic melanoma/brain endothelial cell heparanases. Fiftieth Annual Symposium on Fundamental Cancer Research, Houston, TX, 1997.
  38. Marchetti, D., Shouchun, L., Spohn, W.C., and Carson, D.D. Heparanase and a synthetic peptide of HS-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate. Eighty-ninth A.A.C.R. Meeting, New Orleans, LA, 1998.
  39. Marchetti, D. Heparanase in tumor metastasis. Seventeenth International Cancer Congress, Rio de Janeiro, Brazil, 1998.
  40. Marchetti, D. Molecular determinants of brain metastases. Fourth Meeting of the International Society for Preventive Oncology, Nice, France, 1998.
  41. Walch, E.T., Albino, A., and Marchetti, D. Over-expression of the low-affinity p75 neurotrophin receptor correlates with augmented invasion and heparanase production in human malignant melanoma cells. Ninetieth A.A.C.R. Meeting, Philadelphia, PA, 1999.
  42. Marchetti, D. Human heparanase: a molecular determinant of brain metastasis. Adv. in Enzyme Reg. Meeting, Indiana University Conference Center, Indianapolis, IN, 2000.
  43. Marchetti, D., Li, J., and Shen, R. Brain-metastases associated genes. Eighth International Congress of the Metastasis Research Society, Kensington, England, 2000.
  44. Marchetti, D. Neurotrophin receptors and heparanase: molecular determinants of brain metastasis.  Society for Neuroscience Meeting, New Orleans, LA, 2000.
  45. Marchetti, D., Shen, R., and Li, J. Astrocytes  produce  heparanase and contribute to the metastatic brain specificity of melanoma cells. Meeting of the Society for Neuro- Oncology, Chicago, IL, 2000.
  46. Marchetti, D.  Human heparanase: a molecular determinant of tumor metastasis and angiogenesis.  Ninety-second A.A.C.R. Meeting, New Orleans, LA, 2001.
  47. Marchetti, D.  Human heparanase:  a modulator of brain tumor invasion and angiogenesis. International Meeting on membrane-bound proteolytic enzymes and cancer, Palermo, Italy, 2001.
  48. Marchetti, D., Shen, R., and Li, J.     Human heparanase:  a modulator of brain metastasis.    Fourteenth International Conference of Brain Tumor Research and Therapy, Grove Park Inn, Duke University Medical Center, NC, 2001.
  49. Reiland, J, Roy, M., and Marchetti, D. Human heparanase:  a molecular determinant of brain metastasis and angiogenesis. Society of Neuro-oncology Meeting, San Diego, CA, 2002.
  50. Marchetti, D., Reiland, J., Erwin, B., and Roy, M. Inhibition of heparanase activity   and heparanase-induced angiogenesis by suramin analogues. Cancer Chemoprevention Meeting, Dallas, TX, 2002.
  51. Roy, M., Reiland, J., Chouljenko, V., Kousoulas, K.G., and Marchetti, D. Antisense- mediated suppression of heparanase gene inhibits the invasion of brain-metastatic melanoma cells.   Ninety-Fourth A.A.C.R. Meeting, Washington D.C., 2003.
  52. Marchetti, D., Reiland, J., Greiter-Wilke, A., Galjour, J., Murry, B., Warren, B., and Roy, M. Antisense-mediated suppression of heparanase gene expression inhibits brain metastasis of human/murine brain-metastatic melanoma cells. The 15th International Conference on brain tumor research and therapy, Sorrento, Italy, 2003.
  53. Reiland, J., Sanderson, R., Waguespack, M., Barker, S., Long, R., Carson, D., and Marchetti, D. Heparanase degrades the heparan sulfate  chains  of  cell-surface syndecan-1: implications for tumor cell invasion. Pathobiology of Proteoglycans, 3rd International Conference on proteoglycans, Parma, Italy, 2003.
  54. Roy, M., Reiland, J., Chouljenko, V., Kousoulas, K.G., and Marchetti, D. Antisense- mediated suppression of heparanase inhibits the invasion of brain-metastatic melanoma cells. International Society for Preventive Oncology Meeting, Montreal, Quebec, Canada, 2003.
  55. Reiland, J., Sanderson, R., Waguespack, M., Barker, S., Long, R., Carson, D.D., and Marchetti, D. Heparanase degrades  the  heparan  sulfate chains of cell-surface syndecan- 1: implications for tumor cell invasion. International Society for Preventive  Oncology Meeting, Montreal, Quebec, Canada, 2003.
  56. Reiland, J., Sanderson, R., Waguespack, M., Barker, S., Long, R., Carson, D.D., and Marchetti, D. Heparan sulfate mechanisms in tumorigenic potential and brain metastasis formation. Ninety-Fifth A.A.C.R. Meeting, Orlando, FL, 2004.
  57. Roy, M., Reiland, J., Murry, B., Denkins, Y., Chouljenko, V., Kousoulas, K.G., and Marchetti,          D.           Antisense-mediated          suppression         of     heparanase         gene       inhibits       brain metastases of melanoma cells. Tenth International Meeting of the Metastasis Research Society, Genoa, Italy, 2004.
  58. Aucoin, R., Reiland, J., Roy, M., and Marchetti, D. Dominant-negative CREB Inhi- bits heparanase functionality and melanoma cell invasion. Tenth International Meeting of the Metastasis Research Society, Genoa, Italy, 2004.
  59. Reiland, J., Sanderson, R., Waguespack, M., Barker, S., Long, R., Carson, D.D., and Marchetti, D. Heparanase degrades  the  heparan  sulfate chains of cell-surface syndecan- 1: implications for tumor cell invasion. Tenth International Meeting of the Metastasis Research Society, Genoa, Italy, 2004.
  60. Brown, A., Kirn-Safran, C., Roy, M., Marchetti, D., Farach-Carson, M.C., and   Carson D.D.  Heparanase expression in developing mouse limb.  American Association of Molecular Reproduction Meeting, Washington D.C., 2004.
  61. Reiland, J., Sanderson, R., Waguespack, M., Barker, S., Long, D., Carson, D., and Marchetti, D.  Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. World and Ehrilch Conference, Nürberg, Germany, 2004.
  62. Roy, M., Reiland, J., Murry, B., Chouljenko, V., Kousoulas, K.G., and Marchetti, D. Antisense-mediated modalities in inhibiting heparanase functionality in cancer metastasis. World and Ehrilch Conference, Nürberg, Germany, 2004.
  63. Marchetti, D., Aucoin, R., Reiland, J., and Roy, M. CREB mechanisms on heparanase functionality in invasion and metastasis. Ninety-Sixth A.A.C.R. Meeting, Anaheim, CA, 2005.
  64. Reiland J., Kopecky D., Denkins Y., Kempf D., and  Marchetti, D.  Heparanase alters lipid raft composition in newly developed, highly brain-metastatic melanoma cells. Ninety-Seventh A.A.C.R. Meeting, Washington, D.C., 2006.
  65. Kopecky D., Reiland J., Denkins Y., Kempf D., and  Marchetti, D. Heparanase and lipid rafts in brain metastases.  Thirty-first  FEBS Congress, Instanbul, Turkey, 2006.
  66. Reiland, J., Kempf, D., Roy M., Denkins Y., and Marchetti, D. Heparanases roles in modulating FGF2 binding, signaling and angiogenesis in malignant melanoma. The 6th International Conference on the Adjuvant Therapy of Malignant Melanoma, Stockholm, Sweden, 2006.
  67. Marchetti, D., Reiland, J., Kempf, D., Roy M., and Denkins Y. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. The Third Annual International Melanoma Research Congress, Noordwijk, The Netherlands, 2006.
  68. Reiland, J., Kempf, D., Roy, M., Denkins, Y. and Marchetti, D. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Third Tumor Progression & Therapeutic Resistance Conference, Baltimore, MD, 2006.
  69. Davis, D.W., Marchetti, D., Yan, D., Seiwert, T.Y., Vokes, E.E., Wong, S., Kozloff, M.F.,  Dekker,  A.,  and  Cohen,  E.E.W. Predictive  markers  of  response  in  a  Phase  I/II pharmacodynamic (PD) study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC), AACR-EORTC meeting, San Francisco, CA, 2007.
  70. Marchetti, D.  FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Fourth Dan Duncan Cancer Meeting, BCM, Houston, TX, 2008.
  71. Marchetti, D. Distinct genetic variations and miRNA patterns in hpse according to brain-metastatic cancer progression.  “Development of non-coding RNAs for cancer therapy” M.D. Anderson/BCM Annual Symposium, Houston, TX, 2009.
  72. Marchetti, D.  Heparanase is critically involved in EGFR/HER-2 - mediated breast cancer metastasis to brain.  One-hundredth A.A.C.R. Meeting, Denver, CO, 2009.
  73. Marchetti, D. Heparanase: A critical determinant of breast cancer metastasis to brain. Fifth International Conference on Tumor Microenvironment:  progression, therapy and prevention, Versailles, France, 2009.
  74. Zhang L.,  Sullivan P., Gunaratne P. and Marchetti, D.  MiR-1258: A microRNA inhibiting breast cancer brain metastasis by suppressing heparanase.  CTRC – AACR San Antonio Breast Cancer Symposium, San Antonio, TX, 2009.
  75. Marchetti, D.  Heparanase:  A critical determinant of breast cancer metastasis to brain.  World Cancer Congress - Breast Cancer Conference, Shanghai, China, 2010.
  76. Ridgway L.D., Wetzel M., and Marchetti, D. Heparanase modulates Hh and Wnt3a signaling in human medulloblastoma cells. One-hundredth first A.A.C.R. Meeting, Washington D.C., 2010.
  77. Marchetti, D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Metastasis and the Tumor Microenvironment. MRS-AACR Joint Conference , Philadelphia, PA, 2010.
  78. Marchetti, D. Heparanase mechanisms in brain metastatic breast cancer. 15th World Congress on Advances in Oncology and 13th International Symposium on Molecular Medicine, Loutraki, Greece, 2010.
  79. Marchetti, D. Heparanase and CTCs: a powerful duet in brain metastatic breast cancer Heparanase, “Cancer drug development session”, World Cancer Congress of Gene, Sanshui, Foshan, China, 2010.
  80. Zhang L., Sullivan P., Gunaratne P, Goodman J.C., and Marchetti, D. MicroRNA - 1258 suppresses breast cancer brain metastasis by targeting heparanase. Innovations in Cancer Prevention and Research Conference, The Cancer Prevention and Research Institute of Texas, Austin, TX, 2010.
  81. Marchetti, D. Participant at the First National Conference on Health and Research, sponsored by the Minister of Health of Italy (by invitation only), Cernobbio, Italy, 2010.
  82. Zhang L., Sullivan P., Gunaratne P, Goodman J.C., and Marchetti, D. MicroRNA - 1258 suppresses breast cancer brain metastasis by targeting heparanase. World CTC Summit, Boston, MA, 2010.
  83. Marchetti,  D.  MicroRNA  -1258  suppresses  breast  cancer  brain  metastasis  by targeting heparanase. The Neurotumor Club, Annual A.A.C.R. Meeting, Orlando, FL, 2011.
  84. Marchetti, D. MicroRNA -1258 suppresses breast cancer brain metastasis by targeting heparanase. “New concepts of cancer metastasis”, Joint TuMIC – MRS/EACR Conference, Lisbon, Portugal, 2011.
  85. Marchetti, D. Molecular profiling and signatures of breast cancer brain - homing circulating tumor cells. 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine, Rhodes, Greece, 2011.
  86. Marchetti, D. Molecular signatures of breast cancer brain - homing circulating tumor cells. Third World CTC Summit (by invitation only), San Diego, CA, 2011.
  87. Marchetti D.  Subsets and signatures of circulating tumor cells in breast cancer brain metastasis.  CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, 2011.
  88. Marchetti D. Characterizing breast cancer brain – homing circulating tumor cells. Molecular Targets and Cancer Therapeutics, AACR-NCI-EORTC International Conference, San Francisco, CA, 2011.
  89. Marchetti D. Circulating tumor cells in breast cancer brain metastasis. Frontiers in Cancer Prevention Research, 10th Annual AACR International Conference, Boston, MA, 2011.
  90. Marchetti D.  The characterization of breast cancer brain-homing circulating tumor cells.  Innovations in Cancer Prevention and Research Conference, The Cancer Prevention and Research Institute of Texas (CPRIT), Austin, TX, 2011.
  91. Marchetti D. Combating breast cancer brain metastasis: the CTC signature, 14th International Conference on Metastasis Research, The MRS Society, Brisbane, Australia, 2012
  92. Marchetti D.  Circulating tumor cells: biology and therapeutic implications. The ADAPT Cancer Congress, Washington, DC, 2012.
  93. Marchetti D.  CTC signatures in breast cancer brain metastasis: interrogating mechanisms of dormancy and colonization.  The 6th World CTC USA Summit, Washington (DC),  2012.
  94. Marchetti D. The biology and therapeutic utilities of circulating tumor cells. Cell Culture and Stem Cells Meeting, San Diego, CA, 2013.
  95. Capuana, I., Hoyos, V., Chaktraborty, R., Savoldo, B., Marchetti, D., and Dotti, G. Restored expression of heparanase in tumor-specific T cells enhances their  antitumor effects in a neuroblastoma model. American Society of Gene & Cell Therapy Meeting, Salk Lake City, UT, 2013.
  96. Marchetti, D. The identification and characterization of breast cancer CTCs competent for brain metastasis.  Next Generation Dx Summit, Washington (DC), 2013.
  97. Marchetti, D. The identification and characterization of breast cancer CTCs competent for brain metastasis”,  9th International Symposium on Minimal Residual Cancer, Paris, France, 2013.
  98. Marchetti, D. Characterizing breast cancer brain-homing CTCs. Stem Cells and Cancer - Keystone Symposium, Banffs, Canada, 2014.
  99. Marchetti, D.  Characterizing breast cancer brain-colonizing CTCs.  Tri-Con Conference on CTCs, San Francisco, CA, 2014.
  100. Zhang L, Ridgway L, Wetzel M., Ngo J., Yin W., Kumar D., Goodman J.C., Groves M., and     Marchetti, D.  The identification and characterization of breast cancer CTCs with brain  metastatic  competence. Annual  A.A.C.R.  Meeting  and  the  Neurotumor  Club  of A.A.C.R., San Diego, CA, 2014.
  101. Marchetti, D. The Biology of Circulating Tumor Cells”  2014 Gordon Research Conference on Rare Cells in Circulation: CTCs and metastasis, Mount Holyoke College in South Hadley, Boston, MA, 2014.
  102. Marchetti D.  Characterizing CTCs in Breast Cancer Brain Metastasis.  4th Annual Brain Metastases Research and Emerging Therapy Conference, Marseille, France, 2014.
  103. Marchetti, D.  Mechanisms of CTCs competent for breast cancer brain metastasis, Biology and Treatment of Metastatic Cancers Conference, El-Jadida, Morocco, 2014.
  104. Marchetti, D. Using DEPArray to characterize CTCs competent for breast cancer brain metastasis. The DEPArray User Meeting Group, Silicon Biosystems, Bologna, Italy, 2014.

 

Dario Marchetti

Jack L. Titus Professor

 

  • :(713) 798-2335
    Fax: (713) 798-1956

  • DEPARTMENTDepartment of Pathology & Immunology
    Department of Molecular & Cellular Biology Director, CTC Core Facility
    Baylor College of Medicine
  • COUNTRYUSA